☰

Xikui Liu, Ph.D. - Publications

Affiliations: 
2005 State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Immunology, Cell Biology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Liu X, Zawidzka EM, Li H, Lesch CA, Dunbar J, Bousley D, Zou W, Hu X, Carter LL. RORγ agonists enhance the sustained antitumor activity through intrinsic Tc17 cytotoxicity and Tc1 recruitment. Cancer Immunology Research. PMID 31064778 DOI: 10.1158/2326-6066.Cir-18-0714  0.365
2018 Hu X, Majchrzak K, Liu X, Wyatt MM, Spooner C, Moisan J, Zou W, Carter LL, Paulos CM. In vitro priming of adoptively transferred T cells with a RORγ agonist confers durable memory and stemness in vivo. Cancer Research. PMID 29769201 DOI: 10.1158/0008-5472.Can-17-3973  0.444
2018 Hu X, Liu X, Li H, Zawidzka E, Weems GA, Gao Y, Fox B, Wilkins HJ, Carter L. Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion. Journal of Clinical Oncology. 36: 424-424. DOI: 10.1200/Jco.2018.36.6_Suppl.424  0.399
2018 Carter L, Liu X, Li H, Zawidzka E, Gao Y, Fox B, Weems G, Wilkins HJ, Hu X. RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation. Journal of Clinical Oncology. 36: 171-171. DOI: 10.1200/Jco.2018.36.5_Suppl.171  0.362
2018 Weems GA, Hu X, Liu X, Li H, Bogdan M, Gao Y, Fox B, Wilkins HJ, Carter L. Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion. Journal of Clinical Oncology. 36: 67-67. DOI: 10.1200/Jco.2018.36.4_Suppl.67  0.341
2018 Hu X, Liu X, Li H, Weems G, Zawidzka E, Gao Y, Wilkins HJ, Carter L. Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies Cancer Research. 78: 5566-5566. DOI: 10.1158/1538-7445.Am2018-5566  0.386
2018 Gaur P, Verma V, Nandre R, Vir P, Wang H, Kang B, Carter L, Hu X, Liu X, Gupta S, Khleif S. Abstract 3773: RORγ agonist enhances antitumor effects of agonist anti-OX40 antibody Cancer Research. 78: 3773-3773. DOI: 10.1158/1538-7445.Am2018-3773  0.41
2018 Gaur P, Verma V, Nandre R, Vir P, Wang H, Kang B, Carter L, Hu X, Liu X, Gupta S, Khleif S. Abstract 3762: Novel RORγt agonist induces antitumor immune effect through enhancement of tumor antigen-specific CD8+ T-cell infiltration into the TME Cancer Research. 78: 3762-3762. DOI: 10.1158/1538-7445.Am2018-3762  0.435
2017 Franchi L, Monteleone I, Hao LY, Spahr MA, Zhao W, Liu X, Demock K, Kulkarni A, Lesch CA, Sanchez B, Carter L, Marafini I, Hu X, Mashadova O, Yuan M, et al. Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. Journal of Immunology (Baltimore, Md. : 1950). PMID 28242647 DOI: 10.4049/Jimmunol.1600810  0.368
2016 Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, et al. Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 5: e1254854. PMID 28123897 DOI: 10.1080/2162402X.2016.1254854  0.464
2016 Hu X, Liu X, Moisan J, Paulos C, Wang Y, Spooner C, Lesch C, Morgan R, Mertz D, Bousley D, Taylor C, Huis CV, Skalitzky D, Aicher T, Toogood P, et al. Abstract 565: RORγ agonists regulate immune checkpoint receptors to enhance anti-tumor immunity Cancer Research. 76: 565-565. DOI: 10.1158/1538-7445.Am2016-565  0.396
2015 Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, Wendling JM, Morgan RW, Aicher TD, Carter LL, Toogood PL, Glick GD. Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists. Nature Chemical Biology. 11: 141-7. PMID 25558972 DOI: 10.1038/Nchembio.1714  0.358
2015 Hu X, Moisan J, Majchrzak K, Lesch C, Wang Y, Sanchez B, Liu X, Morgan R, Mertz D, Bousley D, van Huis C, Skalitzky D, Taylor C, Aicher T, Toogood P, et al. RORgamma agonists enhance survival and memory of type 17 T cells and improve anti-tumor activity Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P23  0.356
2015 Hu X, Moisan J, Lesch C, Wang Y, Liu X, Morgan R, Mertz D, Sanchez B, Bousley D, Taylor C, Huis CV, Aicher T, Toogood P, Zou W, Glick G, et al. Abstract 4273: RORγ agonists as a novel immunotherapy approach for cancer Cancer Research. 75: 4273-4273. DOI: 10.1158/1538-7445.Am2015-4273  0.539
2014 Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, Liu X, Hao LY, Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer CA, Boros L, Opipari AW. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. The Journal of Pharmacology and Experimental Therapeutics. 351: 298-307. PMID 25125579 DOI: 10.1124/Jpet.114.218099  0.355
2014 Hu X, Liu X, Morgan R, Moisan J, Hao L, Wang Y, Sanchez B, Lesch C, Bousley D, Taylor C, Aicher T, Toogood P, Zou W, Glick G, Carter L. Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach Journal For Immunotherapy of Cancer. 2: P194. DOI: 10.1186/2051-1426-2-S3-P194  0.48
2013 Liu X, Li H, Zhong B, Blonska M, Gorjestani S, Yan M, Tian Q, Zhang DE, Lin X, Dong C. USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. The Journal of Experimental Medicine. 210: 1575-90. PMID 23825189 DOI: 10.1084/Jem.20122327  0.518
2013 Hao LY, Liu X, Franchi L. Inflammasomes in inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology. 29: 363-9. PMID 23689522 DOI: 10.1097/Mog.0B013E32836157A4  0.383
2013 Zhong B, Liu X, Wang X, Liu X, Li H, Darnay BG, Lin X, Sun SC, Dong C. Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. Science Signaling. 6: ra35. PMID 23674823 DOI: 10.1126/Scisignal.2003708  0.331
2013 Nallaparaju KC, Zhang Y, Liu X, Reynolds JM, Nurieva RI, Dong C. 184 Cytokine. 63: 286. DOI: 10.1016/J.Cyto.2013.06.187  0.436
2012 Zhong B, Liu X, Wang X, Chang SH, Liu X, Wang A, Reynolds JM, Dong C. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nature Immunology. 13: 1110-7. PMID 23042150 DOI: 10.1038/Ni.2427  0.593
2011 Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S, Youssef S. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Molecular and Cellular Biology. 31: 3653-69. PMID 21746882 DOI: 10.1128/Mcb.05020-11  0.619
2009 Yang XO, Angkasekwinai P, Zhu J, Peng J, Liu Z, Nurieva R, Liu X, Chung Y, Chang SH, Sun B, Dong C. Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment. Nature Immunology. 10: 1260-6. PMID 19881507 DOI: 10.1038/Ni.1821  0.501
2009 Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunological Reviews. 229: 88-100. PMID 19426216 DOI: 10.1111/J.1600-065X.2009.00769.X  0.374
2009 Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, Tian Q, Kollias G, Lu S, Graf D, Dong C. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. Journal of Immunology (Baltimore, Md. : 1950). 182: 4516-20. PMID 19342624 DOI: 10.4049/Jimmunol.0803161  0.358
2007 Yang Y, Liu XK, Nguyen T, Bishop C, Graf D, Dong C. Characterization of B7S3 as a novel negative regulator of T cells. Journal of Immunology (Baltimore, Md. : 1950). 178: 3661-7. PMID 17339463 DOI: 10.4049/Jimmunol.178.6.3661  0.351
2005 Liu XK, Clements JL, Gaffen SL. Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells. Molecules and Cells. 20: 339-47. PMID 16404147  0.708
2004 Liu XK, Lin X, Gaffen SL. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. The Journal of Biological Chemistry. 279: 52762-71. PMID 15459204 DOI: 10.1074/jbc.M405764200  0.705
2004 Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. The Journal of Biological Chemistry. 279: 2559-67. PMID 14600152 DOI: 10.1074/Jbc.M308809200  0.604
1996 Gaffen SL, Lai SY, Ha M, Liu X, Hennighausen L, Greene WC, Goldsmith MA. Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. The Journal of Biological Chemistry. 271: 21381-90. PMID 8702919 DOI: 10.1074/Jbc.271.35.21381  0.71
Show low-probability matches.